# US 2012/0252778 A1 · Pyrazolo pyrimidine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252778 A1
- Document ID: US20120252778A1
- Status: Published application
- Kind: A1
- Application number: 13/429,726
- Filed: 2012-03-26
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Novartis AG
- Inventors: Wolfgang MILTZ; Berndt OBERHAUSER; Andrea VAUPEL; Juraj VELCICKY; Klaus WEIGAND; Rajender Reddy LELETI; Yugang LIU; Zhengming DU
- Web page: https://patentgrep.com/patent/US20120252778A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/34: Tobacco-abuse
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 33/08: for Pneumocystis carinii
- A61P 33/12: Schistosomicides
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pyrazolo pyrimidine derivatives, to methods of preparing these, to combinations and pharmaceutical composition comprising these, and to their use in the treatment of diseases and disorders which may for example involve autoimmune diseases, angiogenesis, pain, and/or inflammatory diseases.

## Claims

### Claim 1

A compound of formula (I) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
A is a bivalent linking group selected from the group consisting of:
—CH═CH—, —CH═CH—CH2—, —CH2—CH═CH—, —CH2—CH2—CH2—, —CH═CH—C(O)—, —C(O)—CH═CH—, —CH2—CH2—C(O)—, —C(O)—CH2—CH2—, —C(O)—NH—CH2—, —CH2—NH—C(O)—, —O—CH2—, —CH2—O—, —O—CH2—CH2—, —CH2—CH2—O—,
(wherein a * denote the link (or places of attachment));
R stands for heterocyclyl or cycloalkyl, each of which may be optionally substituted 1 to 4 times; and
R4 is H, C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, cyano or trifluoromethyl.

### Claim 2 (depends on 1)

A compound of claim 1, which is a compound of formula (I′) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
A is a bivalent linking group selected from the group consisting of:
—CH═CH—, —CH═CH—CH2—, —CH2—CH═CH—, —CH2—CH2—CH2—, —CH═CH—C(O)—, —C(O)—CH═CH—, —CH2—CH2—C(O)—, —C(O)—CH2—CH2—, —C(O)—NH—CH2—, —CH2—NH—C(O)—, —O—CH2—, —CH2—O—, —O—CH2—CH2—, —CH2—CH2—O—,
(wherein a * denote the link (or places of attachment));
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, C1-C6 alkoxycarbonyl or tri-C1-C6 alkyl silyloxy; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H, C1-C6 alkyl, C1-C6 alkoxy, halogen, hydroxy, cyano or trifluoromethyl.

### Claim 3 (depends on 1)

A compound of claim 1, which is a compound of formula (I″) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
A is a bivalent linking group selected from the group consisting of:
—CH═CH—, —CH═CH—CH2—, —CH2—CH2—CH2—, —CH═CH—C(O)—, —CH2—CH2—C(O)—, —C(O)—NH—CH2—, —O—CH2—, —O—CH2—CH2—,
(wherein a * denote the link (or places of attachment));
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, C1-C6 alkoxycarbonyl or tri-C1-C6 alkyl silyloxy; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H or C1-C6 alkyl.

### Claim 4 (depends on 1)

A compound according to claim 1, which is a compound of formula (II) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H or C1-C6 alkyl.

### Claim 5 (depends on 1)

A compound according to claim 1, which is a compound of formula (III) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H or C1-C6 alkyl.

### Claim 6 (depends on 1)

A compound according to claim 1, which is a compound of formula (IV) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H or C1-C6 alkyl.

### Claim 7 (depends on 1)

A compound according to claim 1, which is a compound of formula (V) or a pharmaceutically acceptable salt thereof,
wherein
R1 is H or C1-C6 alkyl;
R2 and R3 are independently from each other H or C1-C6 alkyl;
R stands for azetidine, pyrrolidine, piperidine, piperazine, cyclohexane or cyclopentane, each of which may be optionally substituted 1 to 4 times by oxo (═O); hydroxy; C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl, di-C1-C6 alkyl-amino, C1-C6 alkoxy, or C1-C6 alkoxycarbonyl; tetrazole optionally substituted by C1-C6 alkyl; a hydroxypyrrolidine-carbonyl group; a hydroxypyrrolidine-aminocarbonyl group or a hydroxypyrrolidine-carbonylamino group; and R4 is H or C1-C6 alkyl.

### Claim 8 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R1 is C1-C2 alkyl;
R2 and R3 are independently from each other methyl;
R stands for piperidine or piperazine which may be optionally substituted 1 to 2 times by C1-C6 alkyl optionally substituted one or more times by hydroxy, oxo (═O), amino optionally substituted by C1-C6 alkoxycarbonyl, or mono C1-C6 alkyl-amino optionally substituted by C1-C6 alkoxycarbonyl; and
R4 is H.

### Claim 9 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R1 is ethyl;
R2 and R3 are independently from each other methyl;
R stands for 4-piperidinyl or 1-piperazinyl which may be optionally substituted 1 to 2 times by C1-C6 alkyl optionally substituted 1-3 times by hydroxy, oxo (═O), or mono C1-C6 alkyl-amino, with the proviso that the substituent C1-C6 alkyl cannot be unsubstituted when C1-C6 alkyl is attached to a N-atom;
and
R4 is H.

### Claim 10 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:
4-{(E)-2-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-vinyl}-piperidin-4-ol,
4-{(E)-2-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-vinyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester,
3-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-azetidin-3-ol,
3-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-3-hydroxy-azetidine-1-carboxylic acid tert-butyl ester,
4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperidin-4-ol,
4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester,
4-{3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-propyl}-piperidin-4-ol,
4-{3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-propyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester,
(2S,4S)-4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-2-methyl-piperidin-4-ol,
1-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-2-one,
(R)-3-(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-4-hydroxy-piperidin-1-yl)-propane-1,2-diol,
1-(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-4-hydroxy-piperidin-1-yl)-2-methylamino-ethanone,
[2-(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-methyl-carbamic acid tert-butyl ester,
((S)-4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-2-yl)-methanol,
(S)-4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-2-hydroxymethyl-piperazine-1-carboxylic acid tert-butyl ester,
2-Ethyl-5,7-dimethyl-3-{4-[(E)-3-((S)-3-methyl-piperazin-1-yl)-propenyl]-benzyl}-pyrazolo[1,5-a]pyrimidine,
2-Ethyl-3-{4-[(E)-3-((S)-3-methoxymethyl-piperazin-1-yl)-propenyl]-benzyl}-5,7-dimethyl-pyrazolo[1,5-a]pyrimidine,
2-Amino-1-(4-{(E)-3-[4-(2-ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-1-yl)-ethanone,
2-Ethyl-5,7-dimethyl-3-(4-{(E)-3-[4-(1-methyl-1H-tetrazol-5-yl)-piperidin-1-yl]-propenyl}-benzyl)-pyrazolo[1,5-a]pyrimidine,
((S)-4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-2-ylmethyl)-dimethyl-amine,
(R)-2-Dimethylcarbamoyl-4-{(E)-3-[4-(2-ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazine-1-carboxylic acid tert-butyl ester,
(S)-2-Dimethylaminomethyl-4-{(E)-3-[4-(2-ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazine-1-carboxylic acid tert-butyl ester,
2-Ethyl-5,7-dimethyl-3-[4-((E)-3-piperazin-1-yl-propenyl)-benzyl]-pyrazolo[1,5-a]pyrimidine,
(S)-1-(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-1-yl)-3-hydroxy-2-methylamino-propan-1-one,
(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-1-yl)-((2S,3R)-3-hydroxy-pyrrolidin-2-yl)-methanone,
(R)-3-(4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-1-yl)-propane-1,2-diol,
(R)-1-(tert-Butyl-dimethyl-silanyloxy)-3-(4-{(E)-3-[4-(2-ethyl-5,7-dimethyl-pyrazazolo[1,5-]pyrimidin-3-ylmethyl)-phenyl]-allyl}-piperazin-1-yl)-propan-2-ol,
(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1-piperazin-1-yl-propenone,
4-{(E)-3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-acryloyl}-piperazine-1-carboxylic acid tert-butyl ester,
3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1-piperazin-1-yl-propan-1-one,
4-{3-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-propionyl}-piperazine-1-carboxylic acid tert-butyl ester,
4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-N-piperidin-4-ylmethyl-benzamide,
2-Ethyl-5,7-dimethyl-3-[4-(piperidin-4-ylmethoxy)-benzyl]-pyrazolo[1,5-a]pyrimidine,
4-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxymethyl]-piperidine-1-carboxylic acid tert-butyl ester,
{4-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxymethyl]-piperidin-1-yl}-((2S,3R)-3-hydroxy-pyrrolidin-2-yl)-methanone,
4-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxymethyl]-cyclohexylamine,
(2S,3R)-3-Hydroxy-pyrrolidine-2-carboxylic acid {4-[4-(2-ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxymethyl]-cyclohexyl}-amide,
4-{2-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxy]-ethyl}-piperidin-4-ol,
2-Ethyl-5,7-dimethyl-3-[4-(2-piperazin-1-yl-ethoxy)-benzyl]-pyrazolo[1,5-a]pyrimidine,
4-{2-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenoxy]-ethyl}-piperazine-1-carboxylic acid tert-butyl ester,
2-Ethyl-3-{4-[2-((R)-3-methoxymethyl-piperazin-1-yl)-ethoxy]-benzyl}-5,7-dimethyl-pyrazolo[1,5-a]pyrimidine,
1-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-pyrazol-4-ylmethyl}-azet idin-3-ol,
1-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-pyrazol-4-ylmethyl}-azetidin-3-ylamine,
1-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-pyrazol-4-ylmethyl}-piperidin-4-ylamine,
2-Ethyl-5,7-dimethyl-3-[4-(4-piperazin-1-ylmethyl-pyrazol-1-yl)-benzyl]-pyrazolo[1,5-a]pyrimidine,
((R)-4-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-pyrazol-4-ylmethyl}-piperazin-2-yl)-methanol,
2-Ethyl-5,7-dimethyl-3-[4-(4-piperazin-1-ylmethyl-[1,2,3]triazol-1-yl)-benzyl]-pyrazolo[1,5-a]pyrimidine,
4-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-[1,2,3]triazol-4-ylmethyl}-piperidin-4-ol,
4-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-[1,2,3]triazol-4-ylmethyl}-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester,
2-Ethyl-5,7-dimethyl-3-[4-(5-piperidin-4-yl-[1,3,4]oxadiazol-2-yl)-benzyl]-pyrazolo[1,5-a]pyrimidine,
4-{N′-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-benzoyl]-hydrazinocarbonyl}-piperidine-1-carboxylic acid tert-butyl ester,
4-{5-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-[1,3,4]oxadiazol-2-yl}-cyclohexylamine,
4-{N′-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-benzoyl]-hydrazinocarbonyl}-cyclohexyl)-carbamic acid tert-butyl ester,
4-{1-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-1H-[1,2,3]triazol-4-ylmethyl}-piperidin-4-ol,
1-(4-{5-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-[1,3,4]oxadiazol-2-yl}-piperidin-1-yl)-2-methylamino-ethanone, and
(S)-1-(4-{5-[4-(2-Ethyl-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-3-ylmethyl)-phenyl]-[1,3,4]oxadiazol-2-yl}-piperidin-1-yl)-3-hydroxy-2-methylamino-propan-1-one.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A method for treating a patient susceptible to GPR4 modulation comprising administering an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, thereby treating a disease or condition being selected from:
Osteoporosis (juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or corticosteroid therapy or inactivity), gingivitis, periodontitis, Paget's disease, hypercalcemia of malignancy, tumor induced hypercalcemia, metabolic bone disease, cancer, solid tumors, cardiovascular disorders, atherosclerose, myocardial infarction, limb diseases, peripheral arterial occlusive disease, eye diseases, diabetic retinopathy, macular degeneration, uveitis, arthritis, rheumatoid arthritis, osteoarthritis wound healing, skin diseases, inflammatory and obstructive airway diseases, asthma, intrinsic and extrinsic asthma, mild asthma, moderate asthma, severe asthma, bronchitic asthma, exercise induced asthma, occupational asthma and asthma induced following bacterial infection, acute lung injury, acute/adult respiratory distress syndrome, chronic obstructive pulmonary airways or lung diseases, chronic bronchitis, dyspnea associated herewith, emphysema, exacerbation of airways hyperactivity consequent to other drug therapy, bronchitis, acute arachidic, catarrhal, croupus, chronic or phthinoid bronchitis. Pneumoconiosis, aluminosis, anthracosis, asbestosis, chlicosis, ptilosis, siderosis, silicosis, tabacosis byssinosis, eosinophilia, bronchopulmonar aspergillosis, polyarteritis nodosa, eosinophilic granuloma and eosinophil-related disorders affecting the airways occasioned by drug reaction, infections by organisms such as pneumocystis carinii, trypanosoma cruzi, trypanosoma brucei, crithidia fusculata, parasitic diseases such as schistosomiasis and malaria, tumor invasion and metastasis, metachromatic leukodystrophy, muscular dystrophy, amythrophy, autoimmune disease, respiratory disease, immunologically mediated disease, transplant rejection, inflammatory pain, visceral pain, chronic pain, tumor pain, renal tubular acidosis, Crohn's disease, and inflammatory bowel disease.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A pharmaceutical combination or a kit, comprising a) a first agent which is a compound of claim 1, or a pharmaceutically acceptable salt thereof, and b) at least one co-agent.

### Claim 15

(canceled)

### Claim 16 (depends on 1, 14)

The pharmaceutical combination or a kit of claim 14 comprising a) a first agent which is a compound of claim 1, or a pharmaceutically acceptable salt thereof, and b) at least one co-agent selected from an immunosuppressant, immunomodulatory, anti-inflammatory, chemotherapeutic and an anti-infectious agent.
